{"protocolSection":{"identificationModule":{"nctId":"NCT01174563","orgStudyIdInfo":{"id":"ML25200"},"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy","officialTitle":"A Multi-Center Study Investigating the Correlation Between TARCEVA ®-Induced Rash and Efficacy Among EGFR-mutated NSCLC Patients Receiving First-line Therapy"},"statusModule":{"statusVerifiedDate":"2018-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-05-23","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-12-20","type":"ACTUAL"},"completionDateStruct":{"date":"2016-12-20","type":"ACTUAL"},"studyFirstSubmitDate":"2010-08-02","studyFirstSubmitQcDate":"2010-08-02","studyFirstPostDateStruct":{"date":"2010-08-03","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-12-18","resultsFirstSubmitQcDate":"2018-09-14","resultsFirstPostDateStruct":{"date":"2018-09-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2018-09-14","lastUpdatePostDateStruct":{"date":"2018-09-17","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"},"collaborators":[{"name":"Clalit Health Services","class":"OTHER"}]},"descriptionModule":{"briefSummary":"This open-label, single arm study will assess the correlation between Tarceva (erlotinib)-induced rash and efficacy in participants with inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC) receiving first-line therapy for advanced disease. Participants will receive Tarceva at a dose of 150 mg daily orally, with dose adjustments according to protocol depending on toxicity. Anticipated time on study treatment is until disease progression, unacceptable toxicity, or withdrawal due to any reason."},"conditionsModule":{"conditions":["Non-Squamous Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":60,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Single Arm","type":"EXPERIMENTAL","interventionNames":["Drug: erlotinib [Tarceva]"]}],"interventions":[{"type":"DRUG","name":"erlotinib [Tarceva]","description":"150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol","armGroupLabels":["Single Arm"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-free Survival (PFS) According to Grade of Rash","description":"PFS was defined as the time from start of treatment to the date of the first documented progression according to revised Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 or the date of death for any reason in the absence of progressive disease (PD). Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.","timeFrame":"Day 1 of treatment period until disease progression or death (approximately up to 67 months)"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With Erlotinib Dose Reductions Due to Rash Grade 3-4","timeFrame":"Day 1 of treatment period until disease progression or death (approximately up to 67 months)"},{"measure":"Progression-Free Survival (PFS) in Participants With Erlotinib Dose Reductions Due to Rash Grade 3-4","description":"PFS was defined as the time from start of treatment to the date of the first documented progression according to revised Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 or the date of death for any reason in the absence of progressive disease (PD). Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.","timeFrame":"Day 1 of treatment period until disease progression or death (approximately up to 67 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult participants, \\>/= 18 years of age\n* Inoperable, locally advanced, recurrent or metastatic (Stage IIIB or IV) non-small cell lung cancer (NSCLC)\n* Presence of epidermal growth factor receptor (EGFR) mutations\n* Previously untreated with any systemic anti-neoplastic therapy for advanced disease\n* Last dose of a prior systemic anti-neoplastic therapy for early-stage disease \\>/= 4 weeks before study start, and patient recovered from acute toxicities of any previous therapy\n* A life expectancy of at least 12 weeks\n* Able to comply with the study and its follow-up procedures\n* Female participants had to be postmenopausal (24 months of amenorrhea), surgically sterile or agree to use a physical method of contraception. Male participants had to be surgically sterile or agree to use a barrier method of contraception. Women with an intact uterus (unless amenorrhoeic for the last 24 months) had to have a negative pregnancy test (urine or serum) within 3 days prior to erlotinib treatment initiation in the study. Male and female participants had to use effective contraception during the study and for a period of 90 days following the last administration of erlotinib. Acceptable methods of contraception included an established hormonal therapy or intrauterine device for females, and the use of a barrier contraceptive (i.e. diaphragm or condoms)\n\nExclusion Criteria:\n\n* Pregnant or breast feeding women\n* Granulocyte count \\<1.5 x 109/L and platelet count \\<100\\*10\\^9/L\n* Serum bilirubin \\>1.5 upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \\> 2 \\* ULN (or \\>5 \\* ULN if clearly attributable to liver metastasis)\n* Serum creatinine \\>1.5 ULN or creatinine clearance \\<60 mL/min\n* Known allergy or other adverse reaction to study drug or any other related compound\n* Any significant unstable systemic disease (including active infection, grade 4 hypertension, unstable angina, congestive heart failure, hepatic, renal or metabolic disease)\n* Prior systemic anti-neoplastic therapy with HER1/EGFR inhibitors (as small molecule or monoclonal antibody therapy)\n* Newly diagnosed or not yet definitively treated (i.e. stable disease \\>/= 2 months) CNS metastases or spinal cord compression\n* Any significant ophthalmological abnormality, especially those likely to increase the risk of corneal epithelial lesions (the use of contact lenses is not recommended during the study)\n* Participants who could not take oral medication, who required intravenous alimentation, had had prior surgical procedures affecting absorption, or had active peptic ulcer disease\n* Active cancer other than NSCLC, except for basal cell or squamous cell carcinomas of the skin that have been excised and cured","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Haemek Hospital; Oncology","city":"Afula","zip":"18101","country":"Israel","geoPoint":{"lat":32.60907,"lon":35.2892}},{"facility":"Barzilai; Oncology","city":"Ashkelon","zip":"78278","country":"Israel","geoPoint":{"lat":31.66926,"lon":34.57149}},{"facility":"Soroka Medical Center; Oncology Dept","city":"Beersheba","zip":"8410101","country":"Israel","geoPoint":{"lat":31.25181,"lon":34.7913}},{"facility":"Carmel Hospital; Oncology Unit","city":"Haifa","zip":"34362","country":"Israel","geoPoint":{"lat":32.81303,"lon":34.99928}},{"facility":"Rambam Medical Center; Oncology","city":"Haifa","zip":"3525408","country":"Israel","geoPoint":{"lat":32.81303,"lon":34.99928}},{"facility":"Wolfson Hospital; Oncology","city":"Holon","zip":"58100","country":"Israel","geoPoint":{"lat":32.01034,"lon":34.77918}},{"facility":"Shaare Zedek Medical Center; Oncology Dept","city":"Jerusalem","zip":"91031","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Hadassah Ein Karem Hospital; Oncology Dept","city":"Jerusalem","zip":"9112001","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Meir Medical Center; Oncology","city":"Kfar Saba","zip":"4428164","country":"Israel","geoPoint":{"lat":32.175,"lon":34.90694}},{"facility":"Nahariya Hospital; Oncology","city":"Nahariya","zip":"22100","country":"Israel","geoPoint":{"lat":33.00892,"lon":35.09814}},{"facility":"Chaim Sheba Medical Center; Oncology Dept","city":"Ramat Gan","zip":"5262100","country":"Israel","geoPoint":{"lat":32.08227,"lon":34.81065}},{"facility":"Kaplan Medical Center; Oncology Inst.","city":"Rehovot","zip":"7610001","country":"Israel","geoPoint":{"lat":31.89421,"lon":34.81199}},{"facility":"Ziv Medical Center; Oncology Department","city":"Sefad","zip":"13100","country":"Israel"},{"facility":"Sourasky / Ichilov Hospital; Oncology Department","city":"Tel Aviv","zip":"64239-06","country":"Israel","geoPoint":{"lat":32.08088,"lon":34.78057}},{"facility":"Poria Hospital; Oncology","city":"Tiberias","zip":"15208","country":"Israel","geoPoint":{"lat":32.79221,"lon":35.53124}},{"facility":"Assaf Harofeh; Oncology","city":"Ẕerifin","zip":"6093000","country":"Israel","geoPoint":{"lat":31.95731,"lon":34.84852}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 60 participants were enrolled in the study from 12 centers across Israel.","groups":[{"id":"FG000","title":"Erlotinib","description":"Participants received 150 milligrams (mg) of Erlotinib orally daily, from Day 1 of the treatment period until unacceptable toxicity, disease progression or withdrawal due to any reason."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"60"}]},{"type":"Efficacy Set","comment":"Efficacy set included all participants who received at least one dose of study medication.","achievements":[{"groupId":"FG000","numSubjects":"59"}]},{"type":"Safety Set","comment":"Safety set included all participants who received at least one dose of study medication.","achievements":[{"groupId":"FG000","numSubjects":"59"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"60"}]}],"dropWithdraws":[{"type":"Progressive Disease","reasons":[{"groupId":"FG000","numSubjects":"45"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"5"}]},{"type":"Investigator's Discretion","reasons":[{"groupId":"FG000","numSubjects":"5"}]},{"type":"Participant Withdrew Consent","reasons":[{"groupId":"FG000","numSubjects":"3"}]},{"type":"Rash Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Sponsor's decision","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Analysis was performed on all enrolled participants.","groups":[{"id":"BG000","title":"Erlotinib","description":"Participants received 150 milligrams (mg) of Erlotinib orally daily, from Day 1 of the treatment period until unacceptable toxicity, disease progression or withdrawal due to any reason."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"60"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"69.0","spread":"12.3"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"41"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"19"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival (PFS) According to Grade of Rash","description":"PFS was defined as the time from start of treatment to the date of the first documented progression according to revised Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 or the date of death for any reason in the absence of progressive disease (PD). Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.","populationDescription":"Efficacy set included all participants who received at least one dose of study drug. Here, \"Number Analyzed\" represents the number of participants who were evaluable at specified time points.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Day 1 of treatment period until disease progression or death (approximately up to 67 months)","groups":[{"id":"OG000","title":"Erlotinib","description":"Participants received 150 milligrams (mg) of Erlotinib orally daily, from Day 1 of the treatment period until unacceptable toxicity, disease progression or withdrawal due to any reason."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"}]}],"classes":[{"title":"Grade 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.16","lowerLimit":"1.51","upperLimit":"NA","comment":"Upper limit of 95% CI for Grade 0 was not estimated due to low number of participants with the events."}]}]},{"title":"Grade 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.62","lowerLimit":"3.57","upperLimit":"13.48"}]}]},{"title":"Grade 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.00","lowerLimit":"7.31","upperLimit":"23.61"}]}]},{"title":"Grade 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.28","lowerLimit":"10.62","upperLimit":"25.77"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.005","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.58","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.41","ciUpperLimit":"0.83"}]},{"type":"SECONDARY","title":"Percentage of Participants With Erlotinib Dose Reductions Due to Rash Grade 3-4","populationDescription":"Efficacy set included all participants who received at least one dose of study drug. Here, \"Number Analyzed\" represents the number of participants who were evaluable at specified time points.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 1 of treatment period until disease progression or death (approximately up to 67 months)","groups":[{"id":"OG000","title":"Erlotinib","description":"Participants received 150 milligrams (mg) of Erlotinib orally daily, from Day 1 of the treatment period until unacceptable toxicity, disease progression or withdrawal due to any reason."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"}]}],"classes":[{"title":"Rash Grade III","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.5"}]}]},{"title":"Rash Grade IV","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) in Participants With Erlotinib Dose Reductions Due to Rash Grade 3-4","description":"PFS was defined as the time from start of treatment to the date of the first documented progression according to revised Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 or the date of death for any reason in the absence of progressive disease (PD). Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.","populationDescription":"Efficacy set included all participants who received at least one dose of study drug. Here, \"Number Analyzed\" represents the number of participants who were evaluable at specified time points.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Day 1 of treatment period until disease progression or death (approximately up to 67 months)","groups":[{"id":"OG000","title":"Erlotinib","description":"Participants received 150 milligrams (mg) of Erlotinib orally daily, from Day 1 of the treatment period until unacceptable toxicity, disease progression or withdrawal due to any reason."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"}]}],"classes":[{"title":"Rash grade III","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.72","lowerLimit":"7.31","upperLimit":"50.13"}]}]},{"title":"Rash Grade IV","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From signing of informed consent form up to end of study (approximately up to 67 months)","description":"An Adverse Event (AE) can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.","eventGroups":[{"id":"EG000","title":"Erlotinib","description":"Participants received 150 milligrams (mg) of Erlotinib orally daily, from Day 1 of the treatment period until unacceptable toxicity, disease progression or withdrawal due to any reason.","deathsNumAffected":4,"deathsNumAtRisk":59,"seriousNumAffected":19,"seriousNumAtRisk":59,"otherNumAffected":59,"otherNumAtRisk":59}],"seriousEvents":[{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Gastroduodenitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Hematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Ophthalmic herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Fractured sacrum","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Upper limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Hypokalemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Cerebral artery occlusion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":59}]},{"term":"Bronchitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]},{"term":"Pulmonary edema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":59}]}],"otherEvents":[{"term":"Blepharitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":59}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":59}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":59}]},{"term":"Growth of eyelashes","organSystem":"Eye disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":59}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":59}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":59}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":59}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":35,"numAtRisk":59}]},{"term":"Gingivitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":59}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":59}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":59}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":59}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":59}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":59}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":59}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":59}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":59}]},{"term":"Eye infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":59}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":59}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":59}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":59}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":59}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":59}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":59}]},{"term":"Carcinoembryonic antigen increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":59}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":59}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":59}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":59}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":59}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":59}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":59}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":59}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":59}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":59}]},{"term":"Pelvic pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":59}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":59}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":59}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":59}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":59}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":59}]},{"term":"Hirsutism","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":59}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":59}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":55,"numAtRisk":59}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":59}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-La Roche","email":"genentech@druginfo.com","phone":"800 821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"interventionBrowseModule":{"meshes":[{"id":"D000069347","term":"Erlotinib Hydrochloride"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}